{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.7","value":"5880"},{"groupId":"OG001","spread":"83.2","value":"6580"},{"groupId":"OG002","spread":"93.3","value":"10700"},{"groupId":"OG003","spread":"43.9","value":"16000"},{"groupId":"OG004","spread":"57.4","value":"2990"},{"groupId":"OG005","spread":"65.8","value":"3680"},{"comment":"Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as there was only one participant. Individual value reported: 12600 ng\\*h/mL","groupId":"OG006","spread":"NA","value":"NA"},{"groupId":"OG007","spread":"43.4","value":"8960"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"13"}],"units":"Participants"}],"description":"PK: AUC\\[0-8\\] of LY3475070.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 150mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG000","title":"Cohort A - 150mg QD LY3475070"},{"description":"Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG001","title":"Cohort A - 300mg QD LY3475070"},{"description":"Participants received 300mg LY3475070 orally twice daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG002","title":"Cohort A - 300mg BID LY3475070"},{"description":"Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG003","title":"Cohort A - 600mg QD LY3475070"},{"description":"Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG004","title":"Cohort B - 150mg QD LY3475070 + Pembrolizumab"},{"description":"Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG005","title":"Cohort B - 150mg BID LY3475070 + Pembrolizumab"},{"description":"Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG006","title":"Cohort B - 300mg QD LY3475070 + Pembrolizumab"},{"description":"Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study","id":"OG007","title":"Cohort B - 300mg BID LY3475070 + Pembrolizumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All enrolled participants in phase1a who received LY3475070 and had intensively sampled evaluable PK data on cycle 1 day 1.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8 hours post-dose)","title":"Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Eight Hours (AUC[0-8]) of LY3475070","type":"SECONDARY","unitOfMeasure":"nanograms*hours per milliliter (ng*h/mL)"}